Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return...
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
- Conditions
- Interventions
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 379
- Registration Number
- NCT03056755
- Locations
- 🇺🇸
Kaiser Permanente Medical Group, Anaheim, California, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States
Systemic Hormones and Muscle Protein Synthesis
- Conditions
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- University of Nottingham
- Target Recruit Count
- 34
- Registration Number
- NCT03054168
- Locations
- 🇬🇧
Royal Derby Hospital Medical School, Derby, Derbyshire, United Kingdom
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 55
- Registration Number
- NCT03007979
- Locations
- 🇺🇸
University of Nebraska, Lincoln, Nebraska, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
- Conditions
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3246
- Registration Number
- NCT02941926
- Locations
- 🇺🇸
Ventura County Hematology and Oncology, Oxnard, California, United States
🇺🇸Mid Florida Hematology and Onc Ctr, Orange, Florida, United States
🇺🇸Hope Cancer Center of East Texas, Tyler, Texas, United States
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Hamdy A. Azim
- Target Recruit Count
- 160
- Registration Number
- NCT02917005
- Locations
- 🇿🇦
Wits Oncology center, Johannesburg, South Africa
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
- Conditions
- Interventions
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2023-01-17
- Target Recruit Count
- 680
- Registration Number
- NCT02914158
- Locations
- 🇨🇳
Guangdong People's Hospital, Guangzhou, China
🇨🇳Guangzhou First Municipal People's Hospital, Guangzhou, China
🇨🇳Maoming People's Hospital, Maoming, China
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT02907918
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 64
- Registration Number
- NCT02789878
- Locations
- 🇧🇷
Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, SP, Brazil
Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- Pharmatech
- Target Recruit Count
- 41
- Registration Number
- NCT02749825
- Locations
- 🇺🇸
Jazrawi-Atallah, P.C., Brooklyn, New York, United States
🇺🇸Albemarle Urology Clinic, PA, Albemarle, North Carolina, United States
🇺🇸Raj P. Chopra MD, PC, Bloomsburg, Pennsylvania, United States
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Hoffman Oncology
- Target Recruit Count
- 18
- Registration Number
- NCT02626507
- Locations
- 🇺🇸
Hoffman Oncology, Bronx, New York, United States
🇺🇸California Research Institute, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.